Mutations in BRCA1 and BRCA2 increase a woman's lifetime risk of developing breast cancer by 43% to 84%. It was originally postulated that BRCA1/2-associated breast cancers develop more rapidly than sporadic cancers and may lack preinvasive lesions. More recent studies have found preinvasive lesions in prophylactic mastectomy specimens from mutation carriers; however, there is little information on the presence of preinvasive lesions in tissue adjacent to breast cancers. Our aim is to investigate the role of preinvasive lesions in BRCA-associated breast carcinogenesis.
Approximately 7% to 10% of early onset breast cancers and 10% to 15% of ovarian cancers are thought to be hereditary (1) (2) (3) (4) (5) . The majority of these cancers result from germ line mutations in the BRCA1 and BRCA2 genes (6, 7) . Risk factors to carry a mutation in BRCA1 or BRCA2 include diagnosis of breast cancer at an early age (<50 years), diagnosis of ovarian cancer at any age, diagnosis of bilateral breast cancer, diagnosis of breast and ovarian cancer, diagnosis of male breast cancer, family history positive for breast and/or ovarian cancer, and Ashkenazi Jewish ancestry (2, (8) (9) (10) . Women who carry a germ line mutation in BRCA1 or BRCA2 have a 43% to 84% risk of developing breast cancer and a 22% to 39% risk of developing ovarian cancer by age 70 years (6, 11, 12) .
Studies have shown significant differences in the histopathologic features of BRCA1/2-associated breast cancers compared with sporadic breast cancers (13) (14) (15) (16) (17) . BRCA1/2-related tumors are more likely to be of higher grade and poorly differentiated than sporadic breast tumors (13) (14) (15) (16) (17) . BRCA1-associated tumors are also more likely to be negative for estrogen receptor (ER) and progesterone receptor (PR) as compared with sporadic breast cancers. The ER/PR status of BRCA2-associated tumors and of sporadic controls does not seem to differ, as noted in several reports (13, 15, 16) . Although the pathologic characteristics of BRCA1/2-related breast cancers have been described, much less is known about the progression process of BRCA1/ 2-associated versus sporadic breast cancers.
Fifty percent of BRCA-associated breast cancers are interval cancers that occur between two screening mammograms, and the diagnosis is often made in the absence of prior mammographic and pathologic findings (18) (19) (20) . As such, high-risk or preinvasive histopathologic lesions (i.e., atypias or in situ carcinomas) have not been considered to be part of the BRCA1/ 2-related disease spectrum. Moreover, it was previously proposed that BRCA1/2-related tumors may have a different natural history and may progress more quickly (particularly in the case of BRCA1) than sporadic tumors (21, 22) . The Breast Cancer Linkage Consortium study, for example, showed a lower prevalence of ductal carcinoma in situ (DCIS) among BRCA mutation carriers (17, 23) , whereas another study did not (14) . Currently, most of the BRCA risk assessment models do not take the presence of preinvasive lesions, including DCIS, into consideration when calculating the risk of carrying a BRCA mutation (24, 25) . However, recent studies have indeed reported the presence of high-risk preinvasive lesions in tissue obtained during prophylactic mastectomies of BRCA1/2 mutation carriers (22, (26) (27) (28) (29) (30) . None of the studies evaluated the presence of these lesions within the context of a breast cancer progression model in patients that were BRCA mutation carriers.
To further advance the understanding of the role that highrisk preinvasive lesions play in BRCA-associated breast carcinogenesis, we retrospectively evaluated the presence and prevalence of preinvasive high-risk lesions adjacent to invasive breast cancers from BRCA1/2 mutation carriers, as compared with BRCA1/2-negative sporadic breast cancers.
Subjects and Methods

Patients
Between 1997 and 2006, approximately 900 individuals received genetic counseling and testing for BRCA1/2 at the University of Texas M. D. Anderson Cancer Center, and 209 were found to be carriers for a deleterious mutation either in the BRCA1 or BRCA2 gene. Ninety-eight of 209 individuals had a personal history of invasive breast cancer. We reviewed the electronic medical records of those 98 patients for pathology reports related to their breast cancer diagnoses; 73 patients had available pathology at M. D. Anderson Cancer Center. One hundred and forty-six patients with invasive breast cancer who had tested negative for mutations in BRCA1 and BRCA2 were selected as controls and matched to mutation carriers by age ±2 years at a ratio of 2:1. This study was approved by the institutional review board.
Tumor characteristics and histology
Invasive breast cancers. Breast tumor pathology from 146 sporadic cases and 73 BRCA1/2 mutation carriers were evaluated for histologic tumor type, modified Black's nuclear grade, ER status and PR status by immunohistochemistry, HER-2/neu by immunohistochemistry, HER-2/neu gene amplification by fluorescent in situ hybridization, and the presence of adjacent preinvasive lesions. At our institution, all outside breast cases are re-reviewed in a standardized fashion by designated breast pathologists and a new report is issued.
Preinvasive lesions. Adjacent preinvasive lesions included the presence of DCIS, lobular carcinoma in situ, and atypical lobular hyperplasia that occur in the same quadrant or area as the invasive carcinoma. These lesions were evaluated in each case at our institution and their presence was noted in a report which also indicated the presence of an in situ carcinoma when it was found at a distance from the area of the invasive carcinoma because this could represent a multifocal process.
Statistical analyses and methods
Patient and disease characteristics were tabulated according to BRCA1/2 group: BRCA1-positive versus BRCA2-positive versus BRCA-negative (sporadic controls). Fisher's exact test was used to assess the association between preinvasive lesions and other prognostic factors among the groups. Multiple comparisons were done; thus, the P value required to declare statistical significance was adjusted to account for the increase in the probability of finding false-positive results. The significance level was divided by three relating to the three pairwise comparisons of interest (BRCA1/2-positive versus BRCA1/2-negative, BRCA1-positive versus BRCA1/2-negative, and BRCA2-positive versus BRCA1/2-negative) considering each disease characteristic independently. The Bonferroni correction method resulted in a P < 0.05/3 = 0.0167 to be considered statistically significant. All statistical analyses were done using SAS 9.1 (SAS).
Results
Patients Seventy-three patients with breast cancer who were BRCA mutation carriers (46 BRCA1 and 27 BRCA2) were included in the study. The control group consisted of 146 patients with sporadic breast cancer who were negative for the BRCA1/2 mutation. The median age at diagnosis was 42 years of age (21-71 years) for patients with BRCA mutations, and 42 years of age (22-70 years) for sporadic controls. Twenty-five percent of the BRCA mutation carriers and 36% of the controls underwent segmental mastectomy, respectively.
Invasive breast cancers
The invasive carcinomas (n = 219; 73 BRCA1/2-positive and 146 BRCA1/2-negative, controls) were of various histologic types and included ductal (n = 195), lobular (n = 7), medullary (n = 1), sarcomatoid (n = 1), and mixed ductal and lobular (n = 15) types. The histologic types of the invasive cancers were not statistically significantly different in BRCA1 versus BRCA2 mutation carriers.
In general, BRCA1/2-associated breast cancers tended to be higher-grade tumors rather than sporadic breast cancers. This difference was significant when comparing sporadic tumors to BRCA1/2-positive tumors (P ≤ 0.0001). However, when tumors were compared with BRCA1-positive and BRCA2-positive tumors separately, the tumor grade difference remained significant for BRCA1-positive tumors (P ≤ 0.0001) but did not reach statistical significance for BRCA2-positive tumors (P = 0.0330; Table 1 ).
Tumor expression of ER, PR, and HER-2/neu was compared among the mutation status categories of invasive breast carcinomas. BRCA1-positive tumors were significantly more likely to be ER-negative (76.92%, 30 of 39; P ≤ 0.0001) and PR-negative (73.68%, 28 of 38; P = 0.0029; Table 1 ). In contrast, BRCA2-positive tumors showed neither a significant correlation with, nor a trend toward, any ER or PR status. No significant differences in tumor expression of HER-2/neu were noted among tumors in the various mutation status categories regardless of whether HER-2/neu expression was obtained by immunohistochemistry or fluorescent in situ hybridization.
Preinvasive lesions A wide spectrum of preinvasive lesions, including atypical lesions and in situ carcinomas, were found in tissue adjacent to invasive breast carcinomas, both in BRCA1/2 mutation carriers and in BRCA1/2-negative controls. Among BRCA1/2-positive tumors, 59% (43 of 73) had one or more separate histologic types of preinvasive lesion(s) adjacent to invasive tumor tissue compared with 75% (109 of 146) of BRCA1/2-negative tumors. When BRCA1-positive and BRCA2-positive tumors were evaluated separately, there seemed to be a trend toward fewer pathologic preinvasive lesions adjacent to BRCA1-positive tumors (52%, 24 of 46) than were adjacent to BRCA1/2-negative tumors (75%, 109 of 146). There was no difference between BRCA2-positive tumors and BRCA1/ 2-negative tumors in the number of adjacent preinvasive lesions present (70%, 19 of 27 versus 75%, 109 of 146; Table 2 ).
DCIS was by far the most commonly occurring type of preinvasive lesion and was found adjacent to invasive breast cancer in 48% (22 of 46) of BRCA1-positive tumors, in 70% (19 of 27) of BRCA2-positive tumors, and in 71% (103 of 146) of sporadic (BRCA1/2-negative control) tumors ( Table 2 ). The percentage of adjacent DCIS was similar for BRCA1/2-positive tumors and sporadic control tumors (P = 0.049). It was noted that BRCA1-positive invasive breast cancers had a smaller percentage of adjacent preinvasive DCIS tumors compared with BRCA1/2-negative tumors (P = 0.0074) and that the percentage of adjacent DCIS was similar for BRCA2-positive tumors and sporadic control tumors (P = 1). DCIS adjacent to BRCA1/2-positive breast cancers tended to be higher grade than DCIS adjacent to sporadically occurring control tumors (P = 0.0045). 
Discussion
In this study, we evaluated invasive tumor characteristics and the presence and frequency of preinvasive lesions adjacent to BRCA1-positive and BRCA2-positive invasive breast cancers and compared the findings with those for agematched BRCA1/2-negative control tumors. BRCA1-positive tumors were higher grade and were significantly more likely to be ER-negative and PR-negative. Interestingly, no significant differences in tumor expression of HER-2/neu were noted among tumors in the various mutation status categories, which was most probably due to the small number of cases because of missing data.
We found that preinvasive lesions occurred with considerable frequency in BRCA1/2-negative controls as well as in carriers of the BRCA1/2 mutation. In particular, the frequency of preinvasive lesions in sporadic and BRCA2-associateed tumors were similar (75% versus 70%). BRCA1-associated tumors also contained a considerable number, albeit a lower frequency, of preinvasive lesions (59%) compared with BRCA2-associated or sporadic tumors.
Preinvasive lesions, including DCIS, were not always considered to be part of the spectrum of BRCA1/2-positive breast cancers. Sun et al. reviewed a database of BRCA1 mutation carriers and their families and found 200 cases of invasive breast cancer but only 4 cases of DCIS. It was even suggested that perhaps BRCA1/2-positive tumors had a different pattern of tumor progression than sporadically occurring tumors (21) . Similarly, Frank et al. evaluated BRCA mutations from 10,000 individuals tested at Myriad Genetic Laboratories (10) . The prevalence of BRCA mutations was significantly lower in patients ages 50 years and less with DCIS compared with patients with invasive breast cancer. However, subsequent studies in prophylactic mastectomy specimens from BRCA1/2-positive carriers have shown incidental findings of DCIS (18, 22, 26, 27) . Comparison of prophylactic specimens from BRCA1/2 mutation carriers and BRCA-negative individuals showed no significant difference in the prevalence of DCIS, atypical ductal hyperplasia, or lobular neoplasias with no BRCA1/2 mutation but who had a strong family history of breast cancer, and individuals with no family history of breast cancer (22) .
Claus et al. examined the prevalence of BRCA mutations in women with DCIS and reported mutation rates similar to those found for invasive breast cancer (26) . The authors suggested that DCIS is a part of the BRCA cancer syndromes. A very recent study by Hwang et al. evaluated breast cancer outcomes in a retrospective cohort of 129 BRCA-positive and 269 BRCA-negative women and reported that DCIS was equally prevalent in patients who have BRCA mutations as in BRCA noncarriers, suggesting that DCIS may be on the casual pathway to invasive disease (27) . In our study, we likewise found no significant difference between mutation carriers and controls in the prevalence of these preinvasive lesions.
In another study, Hoogerburgge et al. reported that up to 57% of women with a hereditary risk for breast cancer who underwent prophylactic mastectomy were found to have one or more high-risk preinvasive lesions (atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, and DCIS) in excised tissue specimens, although that study had no control group for comparison (28) . The investigators went on to perform a larger study in which they compared the pathology of prophylactic mastectomy tissue specimens from BRCA1/2 mutation carriers with the pathology of prophylactic specimens from individuals at high risk for breast cancer who did not carry the mutation. They found that high-risk preinvasive lesions were more common in women who did not carry a BRCA1/2 mutation than in women Preinvasive Lesions in BRCA1/2-Associated Breast Cancers who did carry the mutation (71% versus 43%, respectively). These investigators also found no significant difference between BRCA1 carriers and BRCA2 carriers in the prevalence of high-risk preinvasive lesions. This study reported atypical lobular hyperplasia to be the most common preinvasive lesion among both BRCA carriers and BRCA noncarriers, and found DCIS to be the least common lesion (29) . Kauff et al. reported that preinvasive lesions were actually more common in prophylactic mastectomy tissue specimens from carriers of the BRCA1/2 mutation than in breast tissue obtained at autopsy from unaffected women with no known hereditary predisposition to breast cancer (30) . In our study, we have observed a similar incidence of DCIS in patients with BRCA1/2-positive tumors compared with BRCA-negative tumors. We also found that other preinvasive lesions, such as (atypical lobular hyperplasia and lobular carcinoma in situ) were frequently seen in BRCA1/2-positive tumors; however, DCIS was the most commonly occurring lesion.
A limitation to our study is that it is a retrospective review; however, at our institution, all cases are reviewed and reported prospectively by designated breast pathologists using the same review and reporting standards so that there is a system in place to use this information in future studies, as this current one.
One other limitation of our study is that the controls had all received genetic testing. It is therefore possible that there is some selection bias in terms of controls and that this group still might represent a high-risk population.
Finally, we have used the Bonferroni correction to address the issues associated with comparisons across multiple groups of patients (BRCA-negative, BRCA1-positive, BRCA2-positive). From a practical perspective, the correction decreases the chances of making a type I error (i.e., rejecting the null hypothesis when it is in fact true) by lowering the P value needed to declare statistical significance and increasing the standard of proof.
Nevertheless, our results provide support for a subsequent prospective analysis in which each specimen will be evaluated with the intention of determining the true prevalence of adjacent preinvasive lesions in both BRCA1/2-associated breast cancers and BRCA1/2-negative controls.
The possible reasons for such large discrepancies in the literature most probably includes patient selection, incomplete pathology review, differences in pathologic definitions, or simply small sample sizes and random variation. It needs to be acknowledged that with relatively small sample sizes, including this study, subset comparisons are problematic and the confidence intervals are potentially large.
In conclusion, it was originally thought that BRCA1/2-related breast cancers do not go through the same steps of tumorigenesis as sporadically occurring breast cancers do. However, the finding of DCIS with considerable frequency in prophylactic mastectomy tissue samples from carriers of the BRCA1/2 mutation supported the theory that BRCA1/2-associated breast cancers and sporadic breast cancers undergo similar tumor development, although no definitive conclusions could be reached.
We have supplied additional evidence to support this model, showing that preinvasive lesions, particularly DCIS, are often found adjacent to BRCA1/2-associated invasive breast cancers. This finding also provides evidence that hereditary breast cancer progresses through the same intermediate steps as sporadic breast cancer does. Therefore, DCIS should be included in the clinical spectrum of hereditary breast cancers and genetic counseling and testing should be considered for patients who have these preinvasive lesions.
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